SD Biosensor, Consecutive Distributor M&As... Moves to Dominate Europe

[Asia Economy Reporter Lee Chun-hee] SD Biosensor announced on the 22nd through a public disclosure that it will acquire the Italian in vitro diagnostic device distributor Relab for 61.9 billion KRW. Accordingly, SD Biosensor will hold 100% of Relab's shares.

SD Biosensor stated that the purpose of acquiring the shares is 'management participation.' Through this contract, SD Biosensor has completed its second merger and acquisition (M&A) this year, following last month's acquisition of the German in vitro diagnostic product distributor Bestbion. The company explained that this aligns with its mid- to long-term growth strategy and its plan to become a 'global top 3 point-of-care in vitro diagnostic company' through active investment in relevant fields.

Italy is the third-largest market in the European in vitro diagnostic market, following Germany and France. Relab, established in 2004, is a distributor of in vitro diagnostic devices supplying reagents and devices for in vitro diagnostics throughout Italy.

Through this acquisition, SD Biosensor plans to actively expand its business in Italy. Currently, SD Biosensor sells rapid molecular diagnostic devices such as the 'Standard M10,' which can confirm COVID-19 infection within one hour.

An SD Biosensor representative said, "Following Germany, we have further strengthened our distribution network in Europe through the M&A of the Italian distributor," adding, "We will continuously expand our distribution network to more smoothly supply SD Biosensor's excellent diagnostic devices and reagents worldwide."

This content was produced with the assistance of AI translation services.